脳疾患モダリティ＆ソフトウェア市場：製品タイプ、患者タイプ、適応症別-2025-2030年の世界予測

脳疾患モダリティ＆ソフトウェア市場は、2023年に151億8,000万米ドルと評価され、2024年には161億1,000万米ドルに達すると予測され、CAGR 5.33％で成長し、2030年には218億4,000万米ドルに達すると予測されています。

脳疾患モダリティ＆ソフトウェア市場には、さまざまな脳関連疾患の診断、管理、治療のために設計されたさまざまな技術やソリューションが含まれます。これには、ニューロイメージングツール、診断プラットフォーム、研究および臨床用途の専用ソフトウェアが含まれます。これらのモダリティの必要性は、アルツハイマー病、パーキンソン病、てんかん、多発性硬化症などの神経疾患の有病率の増加に起因しており、正確な診断と効果的な管理のための高度なツールが必要とされています。これらの技術は、病院、研究センター、製薬会社、さらには在宅医療の現場で応用され、神経学的研究、個別化医療、患者の転帰改善に大きく貢献しています。最終用途の範囲はヘルスケアプロバイダー、研究機関、患者に及んでおり、この市場の適用範囲の広さと神経学的健康増進における重要な役割を裏付けています。

主な成長要因は、世界人口の高齢化、技術の進歩、神経学研究に対する政府資金の増加などです。AIと機械学習の統合は、リアルタイムの脳疾患予測と個別化治療計画の新たな機会を生み出しています。注目すべき機会は、資源が限られた環境でも利用できる携帯可能で費用対効果の高い治療法の開発や、遺伝子・分子データを活用した精密医療の革新にあります。しかし、コストが高い、新興国市場では先端技術へのアクセスが限られている、規制要件が厳しいといった課題は、市場の成長に影響を与えています。さらに、神経学的健康データに関連するデータプライバシーへの懸念も課題となっています。

研究開発では、包括的な脳の健康評価のために、さまざまな種類のデータのシームレスな統合を促進する、使いやすく相互運用可能なプラットフォームの開発に注力すべきです。ハイテク企業との協力関係を模索することは、魅力的なデジタルヘルス戦略に新たな視点を提供することができます。市場力学はダイナミックで研究集約型であり、未解決のニーズに対応するためには継続的なイノベーションが不可欠です。倫理基準を守り、市場の信頼と受容を促進するために規制の枠組みを確実に遵守しながら、患者中心の費用対効果の高いソリューションに注力することで、企業は成功することができます。

市場力学：急速に進化する脳疾患モダリティ＆ソフトウェア市場の主要市場インサイトを公開

脳疾患モダリティ＆ソフトウェア市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 脳障害の有病率と、診断を求める意識の高まり
  • 脳疾患管理におけるデジタルソリューションの使用を奨励する政府の取り組み
  • 脳疾患検査における神経画像モダリティの採用増加
• 市場抑制要因
  • 検査機器へのソフトウェア技術の統合の複雑さ
• 市場機会
  • AIやMLに基づく先進的な脳疾患ソフトウェアのイントロダクション
  • 脳疾患治療センターの拡大・設立への投資
• 市場の課題
  • データプライバシーとセキュリティ侵害に関する懸念

ポーターのファイブフォース：脳疾患モダリティ＆ソフトウェア市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：脳疾患モダリティ＆ソフトウェア市場における外部からの影響の把握

外部マクロ環境要因は、脳疾患モダリティ＆ソフトウェア市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析脳疾患モダリティ＆ソフトウェア市場における競合情勢の把握

脳疾患モダリティ＆ソフトウェア市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス脳疾患モダリティ＆ソフトウェア市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、脳疾患モダリティ＆ソフトウェア市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨脳疾患モダリティ＆ソフトウェア市場における成功への道筋を描く

脳疾患モダリティ＆ソフトウェア市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 脳疾患の蔓延と診断を求めることに関する意識の高まり
    • 脳疾患管理におけるデジタルソリューションの利用を奨励する政府の取り組み
    • 脳疾患検査における神経画像診断法の採用増加
  • 抑制要因
    • 試験装置にソフトウェア技術を統合することの複雑さ
  • 機会
    • AIとMLに基づく高度な脳疾患ソフトウェアのイントロダクション
    • 脳疾患治療センターの拡張と設立への投資
  • 課題
    • データのプライバシーとセキュリティ侵害に関する懸念
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 脳疾患モダリティ＆ソフトウェア市場：製品別

• 脳分析ソフトウェア
• 脳画像診断法
  • CT装置
  • MRI装置
  • PETデバイス
  • PET-CT
  • PET-MRI

第7章 脳疾患モダリティ＆ソフトウェア市場患者タイプ別

• 大人
• 乳児
• 小児科

第8章 脳疾患モダリティ＆ソフトウェア市場適応症別

• 脳疾患
  • 脳腫瘍
  • 中枢神経系がん
  • 特発性てんかん
  • 虚血性脳卒中
• 神経変性疾患
  • アルツハイマー病
  • 運動ニューロン疾患
  • 多発性硬化症
  • パーキンソン病

第9章 南北アメリカの脳疾患モダリティ＆ソフトウェア市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の脳疾患モダリティ＆ソフトウェア市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの脳疾患モダリティ＆ソフトウェア市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Aspect Imaging Ltd.
• Brainomix Limited
• Canon Medical Systems Corporation
• Carestream Health, Inc.
• Esaote S.p.A.
• Fujifilm Holdings Corporation
• General Electric Company,
• Imaging Biometrics LLC
• International Business Machines Corporation
• IXICO plc.
• Koninklijke Philips N.V.,
• MIM Software, Inc.
• Quantib B.V.
• ScienceSoft USA Corporation
• Siemens Healthineers AG
• VUNO Inc.

LIST OF FIGURES

• FIGURE 1. BRAIN DISEASE MODALITIES & SOFTWARE MARKET RESEARCH PROCESS
• FIGURE 2. BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. BRAIN DISEASE MODALITIES & SOFTWARE MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. BRAIN DISEASE MODALITIES & SOFTWARE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. BRAIN DISEASE MODALITIES & SOFTWARE MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. BRAIN DISEASE MODALITIES & SOFTWARE MARKET DYNAMICS
• TABLE 7. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN ANALYSIS SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CT DEVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MRI DEVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PET DEVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PET-CT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PET-MRI, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INFANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CENTRAL NERVOUS SYSTEM CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY IDIOPATHIC EPILEPSY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MOTOR NEURON DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 44. ARGENTINA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 46. BRAZIL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 47. BRAZIL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, 2018-2030 (USD MILLION)
• TABLE 48. BRAZIL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 49. BRAZIL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 50. BRAZIL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, 2018-2030 (USD MILLION)
• TABLE 51. BRAZIL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 52. CANADA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 53. CANADA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, 2018-2030 (USD MILLION)
• TABLE 54. CANADA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 55. CANADA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 56. CANADA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, 2018-2030 (USD MILLION)
• TABLE 57. CANADA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 58. MEXICO BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 59. MEXICO BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, 2018-2030 (USD MILLION)
• TABLE 60. MEXICO BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 61. MEXICO BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 62. MEXICO BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, 2018-2030 (USD MILLION)
• TABLE 63. MEXICO BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 64. UNITED STATES BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 65. UNITED STATES BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, 2018-2030 (USD MILLION)
• TABLE 66. UNITED STATES BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 67. UNITED STATES BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 68. UNITED STATES BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, 2018-2030 (USD MILLION)
• TABLE 69. UNITED STATES BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 70. UNITED STATES BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 71. ASIA-PACIFIC BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 72. ASIA-PACIFIC BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, 2018-2030 (USD MILLION)
• TABLE 73. ASIA-PACIFIC BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 74. ASIA-PACIFIC BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 75. ASIA-PACIFIC BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, 2018-2030 (USD MILLION)
• TABLE 76. ASIA-PACIFIC BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 77. ASIA-PACIFIC BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 78. AUSTRALIA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 79. AUSTRALIA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, 2018-2030 (USD MILLION)
• TABLE 80. AUSTRALIA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 81. AUSTRALIA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 82. AUSTRALIA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, 2018-2030 (USD MILLION)
• TABLE 83. AUSTRALIA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 84. CHINA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 85. CHINA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, 2018-2030 (USD MILLION)
• TABLE 86. CHINA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 87. CHINA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 88. CHINA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, 2018-2030 (USD MILLION)
• TABLE 89. CHINA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 90. INDIA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 91. INDIA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, 2018-2030 (USD MILLION)
• TABLE 92. INDIA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 93. INDIA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 94. INDIA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, 2018-2030 (USD MILLION)
• TABLE 95. INDIA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 96. INDONESIA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 97. INDONESIA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, 2018-2030 (USD MILLION)
• TABLE 98. INDONESIA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 99. INDONESIA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 100. INDONESIA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, 2018-2030 (USD MILLION)
• TABLE 101. INDONESIA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 102. JAPAN BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 103. JAPAN BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, 2018-2030 (USD MILLION)
• TABLE 104. JAPAN BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 105. JAPAN BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 106. JAPAN BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, 2018-2030 (USD MILLION)
• TABLE 107. JAPAN BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 108. MALAYSIA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 109. MALAYSIA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, 2018-2030 (USD MILLION)
• TABLE 110. MALAYSIA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 111. MALAYSIA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 112. MALAYSIA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, 2018-2030 (USD MILLION)
• TABLE 113. MALAYSIA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 114. PHILIPPINES BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 115. PHILIPPINES BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, 2018-2030 (USD MILLION)
• TABLE 116. PHILIPPINES BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 117. PHILIPPINES BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 118. PHILIPPINES BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, 2018-2030 (USD MILLION)
• TABLE 119. PHILIPPINES BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 120. SINGAPORE BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 121. SINGAPORE BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, 2018-2030 (USD MILLION)
• TABLE 122. SINGAPORE BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 123. SINGAPORE BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 124. SINGAPORE BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, 2018-2030 (USD MILLION)
• TABLE 125. SINGAPORE BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH KOREA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH KOREA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH KOREA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH KOREA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH KOREA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH KOREA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 132. TAIWAN BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 133. TAIWAN BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, 2018-2030 (USD MILLION)
• TABLE 134. TAIWAN BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 135. TAIWAN BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 136. TAIWAN BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, 2018-2030 (USD MILLION)
• TABLE 137. TAIWAN BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 138. THAILAND BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 139. THAILAND BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, 2018-2030 (USD MILLION)
• TABLE 140. THAILAND BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 141. THAILAND BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 142. THAILAND BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, 2018-2030 (USD MILLION)
• TABLE 143. THAILAND BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 144. VIETNAM BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 145. VIETNAM BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, 2018-2030 (USD MILLION)
• TABLE 146. VIETNAM BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 147. VIETNAM BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 148. VIETNAM BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, 2018-2030 (USD MILLION)
• TABLE 149. VIETNAM BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 150. EUROPE, MIDDLE EAST & AFRICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 151. EUROPE, MIDDLE EAST & AFRICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, 2018-2030 (USD MILLION)
• TABLE 152. EUROPE, MIDDLE EAST & AFRICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, 2018-2030 (USD MILLION)
• TABLE 155. EUROPE, MIDDLE EAST & AFRICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 156. EUROPE, MIDDLE EAST & AFRICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 157. DENMARK BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 158. DENMARK BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, 2018-2030 (USD MILLION)
• TABLE 159. DENMARK BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 160. DENMARK BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 161. DENMARK BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, 2018-2030 (USD MILLION)
• TABLE 162. DENMARK BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 163. EGYPT BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 164. EGYPT BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, 2018-2030 (USD MILLION)
• TABLE 165. EGYPT BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 166. EGYPT BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 167. EGYPT BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, 2018-2030 (USD MILLION)
• TABLE 168. EGYPT BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 169. FINLAND BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 170. FINLAND BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, 2018-2030 (USD MILLION)
• TABLE 171. FINLAND BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 172. FINLAND BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 173. FINLAND BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, 2018-2030 (USD MILLION)
• TABLE 174. FINLAND BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 175. FRANCE BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 176. FRANCE BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, 2018-2030 (USD MILLION)
• TABLE 177. FRANCE BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 178. FRANCE BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 179. FRANCE BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, 2018-2030 (USD MILLION)
• TABLE 180. FRANCE BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 181. GERMANY BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 182. GERMANY BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, 2018-2030 (USD MILLION)
• TABLE 183. GERMANY BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 184. GERMANY BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 185. GERMANY BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, 2018-2030 (USD MILLION)
• TABLE 186. GERMANY BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 187. ISRAEL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 188. ISRAEL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, 2018-2030 (USD MILLION)
• TABLE 189. ISRAEL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 190. ISRAEL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 191. ISRAEL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, 2018-2030 (USD MILLION)
• TABLE 192. ISRAEL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 193. ITALY BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 194. ITALY BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, 2018-2030 (USD MILLION)
• TABLE 195. ITALY BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 196. ITALY BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 197. ITALY BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, 2018-2030 (USD MILLION)
• TABLE 198. ITALY BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 199. NETHERLANDS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 200. NETHERLANDS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, 2018-2030 (USD MILLION)
• TABLE 201. NETHERLANDS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 202. NETHERLANDS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 203. NETHERLANDS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, 2018-2030 (USD MILLION)
• TABLE 204. NETHERLANDS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 205. NIGERIA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 206. NIGERIA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, 2018-2030 (USD MILLION)
• TABLE 207. NIGERIA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 208. NIGERIA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 209. NIGERIA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, 2018-2030 (USD MILLION)
• TABLE 210. NIGERIA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 211. NORWAY BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 212. NORWAY BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, 2018-2030 (USD MILLION)
• TABLE 213. NORWAY BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 214. NORWAY BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 215. NORWAY BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, 2018-2030 (USD MILLION)
• TABLE 216. NORWAY BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 217. POLAND BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 218. POLAND BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, 2018-2030 (USD MILLION)
• TABLE 219. POLAND BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 220. POLAND BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 221. POLAND BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, 2018-2030 (USD MILLION)
• TABLE 222. POLAND BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 223. QATAR BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 224. QATAR BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, 2018-2030 (USD MILLION)
• TABLE 225. QATAR BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 226. QATAR BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 227. QATAR BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, 2018-2030 (USD MILLION)
• TABLE 228. QATAR BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 229. RUSSIA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 230. RUSSIA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, 2018-2030 (USD MILLION)
• TABLE 231. RUSSIA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 232. RUSSIA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 233. RUSSIA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, 2018-2030 (USD MILLION)
• TABLE 234. RUSSIA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 235. SAUDI ARABIA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 236. SAUDI ARABIA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, 2018-2030 (USD MILLION)
• TABLE 237. SAUDI ARABIA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 238. SAUDI ARABIA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 239. SAUDI ARABIA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, 2018-2030 (USD MILLION)
• TABLE 240. SAUDI ARABIA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 241. SOUTH AFRICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 242. SOUTH AFRICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, 2018-2030 (USD MILLION)
• TABLE 243. SOUTH AFRICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 244. SOUTH AFRICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 245. SOUTH AFRICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, 2018-2030 (USD MILLION)
• TABLE 246. SOUTH AFRICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 247. SPAIN BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 248. SPAIN BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, 2018-2030 (USD MILLION)
• TABLE 249. SPAIN BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 250. SPAIN BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 251. SPAIN BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, 2018-2030 (USD MILLION)
• TABLE 252. SPAIN BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 253. SWEDEN BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 254. SWEDEN BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, 2018-2030 (USD MILLION)
• TABLE 255. SWEDEN BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 256. SWEDEN BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 257. SWEDEN BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, 2018-2030 (USD MILLION)
• TABLE 258. SWEDEN BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 259. SWITZERLAND BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 260. SWITZERLAND BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, 2018-2030 (USD MILLION)
• TABLE 261. SWITZERLAND BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 262. SWITZERLAND BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 263. SWITZERLAND BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, 2018-2030 (USD MILLION)
• TABLE 264. SWITZERLAND BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 265. TURKEY BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 266. TURKEY BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, 2018-2030 (USD MILLION)
• TABLE 267. TURKEY BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 268. TURKEY BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 269. TURKEY BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, 2018-2030 (USD MILLION)
• TABLE 270. TURKEY BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 271. UNITED ARAB EMIRATES BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 272. UNITED ARAB EMIRATES BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, 2018-2030 (USD MILLION)
• TABLE 273. UNITED ARAB EMIRATES BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 274. UNITED ARAB EMIRATES BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 275. UNITED ARAB EMIRATES BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, 2018-2030 (USD MILLION)
• TABLE 276. UNITED ARAB EMIRATES BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 277. UNITED KINGDOM BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 278. UNITED KINGDOM BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN IMAGING MODALITIES, 2018-2030 (USD MILLION)
• TABLE 279. UNITED KINGDOM BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 280. UNITED KINGDOM BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 281. UNITED KINGDOM BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY BRAIN DISEASES, 2018-2030 (USD MILLION)
• TABLE 282. UNITED KINGDOM BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 283. BRAIN DISEASE MODALITIES & SOFTWARE MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 284. BRAIN DISEASE MODALITIES & SOFTWARE MARKET, FPNV POSITIONING MATRIX, 2023

The Brain Disease Modalities & Software Market was valued at USD 15.18 billion in 2023, expected to reach USD 16.11 billion in 2024, and is projected to grow at a CAGR of 5.33%, to USD 21.84 billion by 2030.

The Brain Disease Modalities & Software market encompasses a range of technologies and solutions designed for diagnosing, managing, and treating various brain-related conditions. This includes neuroimaging tools, diagnostic platforms, and specialized software for research and clinical applications. The necessity of these modalities arises from the increasing prevalence of neurological disorders such as Alzheimer's, Parkinson's, epilepsy, and multiple sclerosis, necessitating advanced tools for accurate diagnosis and effective management. These technologies are applied in hospitals, research centers, pharmaceuticals, and even home care settings, significantly contributing to neurological research, personalized medicine, and improved patient outcomes. The end-use scope extends across healthcare providers, research institutes, and patients, underscoring the market's broad applicability and critical role in enhancing neurological health.

Key growth factors include the aging global population, technological advancements, and increased government funding for neurological research. The integration of AI and machine learning is creating new opportunities for real-time brain disease predictions and personalized treatment plans. Notable opportunities lie in the development of portable and cost-effective modalities that can be accessed in resource-limited settings, as well as innovations in precision medicine that leverage genetic and molecular data. However, challenges such as high costs, limited access to advanced technologies in developing regions, and stringent regulatory requirements impact market growth. Furthermore, data privacy concerns related to neurological health data also pose a challenge.

Innovation and research should focus on developing user-friendly, interoperable platforms that facilitate the seamless integration of various data types for comprehensive brain health assessments. Exploring collaborations with tech companies can provide fresh perspectives on engaging digital health strategies. The Brain Disease Modalities & Software market is dynamic and research-intensive, where continuous innovation is crucial for addressing unmet needs. Businesses can thrive by focusing on patient-centric and cost-effective solutions while upholding ethical standards and ensuring compliance with regulatory frameworks to foster market trust and acceptance.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Brain Disease Modalities & Software Market

The Brain Disease Modalities & Software Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Prevalence of brain disorders and increasing awareness regarding seeking diagnosis
  • Government initiatives encouraging the use of digital solutions in brain disease management
  • Increasing adoption of neuroimaging modalities for brain disease testing
• Market Restraints
  • Complexities of integrating software technologies in testing equipment
• Market Opportunities
  • Introduction of advanced brain disease software based on AI and ML
  • Investments in the expansion and establishment of brain disease treatment centers
• Market Challenges
  • Concerns associated with data privacy and security breaches

Porter's Five Forces: A Strategic Tool for Navigating the Brain Disease Modalities & Software Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Brain Disease Modalities & Software Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Brain Disease Modalities & Software Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Brain Disease Modalities & Software Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Brain Disease Modalities & Software Market

A detailed market share analysis in the Brain Disease Modalities & Software Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Brain Disease Modalities & Software Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Brain Disease Modalities & Software Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Brain Disease Modalities & Software Market

A strategic analysis of the Brain Disease Modalities & Software Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Brain Disease Modalities & Software Market, highlighting leading vendors and their innovative profiles. These include Aspect Imaging Ltd., Brainomix Limited, Canon Medical Systems Corporation, Carestream Health, Inc., Esaote S.p.A., Fujifilm Holdings Corporation, General Electric Company,, Imaging Biometrics LLC, International Business Machines Corporation, IXICO plc., Koninklijke Philips N.V.,, MIM Software, Inc., Quantib B.V., ScienceSoft USA Corporation, Siemens Healthineers AG, and VUNO Inc..

Market Segmentation & Coverage

This research report categorizes the Brain Disease Modalities & Software Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Brain Analysis Software and Brain Imaging Modalities. The Brain Imaging Modalities is further studied across CT Devices, MRI Devices, PET Devices, PET-CT, and PET-MRI.
• Based on Patient Type, market is studied across Adults, Infants, and Pediatrics.
• Based on Indication, market is studied across Brain Diseases and Neurodegenerative Diseases. The Brain Diseases is further studied across Brain Cancer, Central Nervous System Cancer, Idiopathic Epilepsy, and Ischemic Stroke. The Neurodegenerative Diseases is further studied across Alzheimer's Disease, Motor Neuron Disease, Multiple Sclerosis, and Parkinson's Disease.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Prevalence of brain disorders and increasing awareness regarding seeking diagnosis
    • 5.1.1.2. Government initiatives encouraging the use of digital solutions in brain disease management
    • 5.1.1.3. Increasing adoption of neuroimaging modalities for brain disease testing
  • 5.1.2. Restraints
    • 5.1.2.1. Complexities of integrating software technologies in testing equipment
  • 5.1.3. Opportunities
    • 5.1.3.1. Introduction of advanced brain disease software based on AI and ML
    • 5.1.3.2. Investments in the expansion and establishment of brain disease treatment centers
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns associated with data privacy and security breaches
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Brain Disease Modalities & Software Market, by Product

• 6.1. Introduction
• 6.2. Brain Analysis Software
• 6.3. Brain Imaging Modalities
  • 6.3.1. CT Devices
  • 6.3.2. MRI Devices
  • 6.3.3. PET Devices
  • 6.3.4. PET-CT
  • 6.3.5. PET-MRI

7. Brain Disease Modalities & Software Market, by Patient Type

• 7.1. Introduction
• 7.2. Adults
• 7.3. Infants
• 7.4. Pediatrics

8. Brain Disease Modalities & Software Market, by Indication

• 8.1. Introduction
• 8.2. Brain Diseases
  • 8.2.1. Brain Cancer
  • 8.2.2. Central Nervous System Cancer
  • 8.2.3. Idiopathic Epilepsy
  • 8.2.4. Ischemic Stroke
• 8.3. Neurodegenerative Diseases
  • 8.3.1. Alzheimer's Disease
  • 8.3.2. Motor Neuron Disease
  • 8.3.3. Multiple Sclerosis
  • 8.3.4. Parkinson's Disease

9. Americas Brain Disease Modalities & Software Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Brain Disease Modalities & Software Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Brain Disease Modalities & Software Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Aspect Imaging Ltd.
• 2. Brainomix Limited
• 3. Canon Medical Systems Corporation
• 4. Carestream Health, Inc.
• 5. Esaote S.p.A.
• 6. Fujifilm Holdings Corporation
• 7. General Electric Company,
• 8. Imaging Biometrics LLC
• 9. International Business Machines Corporation
• 10. IXICO plc.
• 11. Koninklijke Philips N.V.,
• 12. MIM Software, Inc.
• 13. Quantib B.V.
• 14. ScienceSoft USA Corporation
• 15. Siemens Healthineers AG
• 16. VUNO Inc.